Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
|
31310053 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, cell proliferation via the GFRA2-PTEN-PI3K/AKT axis may represent new target to develop treatments for neuroblastoma.
|
30722993 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroprotection of miR-214 against isoflurane-induced neurotoxicity involves the PTEN/PI3K/Akt pathway in human neuroblastoma cell line SH-SY5Y.
|
31704096 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we found NLGN3 promoted neuroblastoma cell proliferation and growth through activating PI3K/AKT pathway and providing a new target for neuroblastoma therapy.
|
31150649 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this reason, the present study investigated the presence of such mutations in neuroblastomas (NBs) and tested NB cell lines for sensitivity to FGFR and phosphoinositide 3‑kinase (PI3K) inhibitors.
|
31638167 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
|
29352113 |
2018 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This decline in mTOR activity was accompanied by an increase in phosphoinositide 3 kinase (PI3K)/Akt activity and a parallel increase in p-tau (Ser<sup>396</sup>) but not p-tau (Ser<sup>262</sup>) in differentiated SH-SY5Y neuroblastoma cells.
|
29398519 |
2018 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/Akt/mTOR signaling pathway correlates with oncogenesis, poor prognosis and chemotherapy resistance in NB.
|
29499203 |
2018 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protective Effects of Fisetin Against 6-OHDA-Induced Apoptosis by Activation of PI3K-Akt Signaling in Human Neuroblastoma SH-SY5Y Cells.
|
29204750 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autophagy markers were also measured in cypermethrin-treated neuroblastoma cells in the presence of 3-methyl adenine, a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) class III inhibitor; vinblastine, an autophagosome elongation inhibitor; bafilomycin A1, an autophagolysosome and lysosome fusion/abnormal acidification inhibitor or torin 1, a mechanistic target of rapamycin inhibitor.
|
28840510 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data also suggest that the phosphoinositide 3-kinase (PI3K) inhibitors may provide new opportunities for the treatment of the <i>MYCN</i>-amplified neuroblastoma subtype.
|
29137381 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.
|
28919254 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SF1126 inhibits BRD4 bromodomain binding to acetylated lysine residues with histone H3 as well as PI3K activity in the MYCN amplified neuroblastoma cell line IMR-32.
|
28881723 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
|
27649927 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activating mutations of the NRAS (neuroblastoma rat sarcoma viral oncogene) protein kinase, present in many cancers, induce a constitutive activation of both the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway and the PI(3)K-AKT-mTOR, pathway.
|
27533468 |
2016 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, NVP-BEZ235, a potent dual PI3K and mTOR inhibitor have not shown beneficial effects on neuroblastoma especially in terms of apoptosis induction as a single agent.
|
27278249 |
2016 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI103 combined doxorubicin significantly inhibits the growth of established NB tumors, induced apoptosis of tumor cells, and improved the survival of mice in vivo Taken together, our findings suggest that PI3K inhibition seems to be a promising option to sensitize tumor cells for chemotherapy in NB, which may be effective in the treatment of NBs.
|
26224681 |
2016 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that PI3K Class IIβ (PI3KC2β) and its regulator intersectin 1 (ITSN1) are highly expressed in primary NB tumors and cell lines.
|
25622909 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that targeting PI3K and mTORC2 in aggressive neuroblastomas with an immature phenotype may improve therapeutic efficacy.
|
26432405 |
2015 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that PI3K/Akt pathway is crucial for the upregulation of P2X7R expression in serum-deprived neuroblastoma cells, circumstance that facilitates cell proliferation in the absence of trophic support.
|
26687764 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
|
25228590 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell growth, but no additional growth inhibitory effects were detected when the two classes of drugs were combined.
|
25134527 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies have demonstrated that PI3K/AKT signaling is critical for the oncogenic transformations induced by gastrin-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.
|
23468863 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of neuroblastoma cells with the dual PI3K/mTOR inhibitor PI-103 activated FOXO3a and triggered apoptosis.
|
23378341 |
2013 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that p37δ, a kinase-dead isoform of the PI3K catalytic subunit p110δ, is over-expressed in neuroblastoma tumors, and that it correlates with the activation of both PI3K/Akt- and RAS-signaling pathways.
|
24026661 |
2013 |